crenolanib

Overview

Crenolanib is a selective inhibitor of PDGFRA, PDGFRB, and FLT3 kinases. It is nominated as a therapeutic option for tumors with PDGFRA amplification or activating mutations, particularly in the context of co-amplified KIT/PDGFRA/KDR at chromosome 4q12.

Evidence in the corpus

• Nominated for Triple-WT melanoma subtype (14% of 318 TCGA cases; no hot-spot BRAF/RAS/NF1) to target co-amplified PDGFRA/KDR at 4q12 alongside imatinib, dasatinib, sorafenib, regorafenib, and pazopanib PMID:26091043

Resistance mechanisms

Cancer types (linked)

• MEL

Sources

This page was processed by crosslinker on 2026-05-14.